The overall goal of our Consortium is to elucidate the immunologic mechanisms of leading HIV-1 prophylactic vaccines and eradication strategies. Our overall hypothesis is that understanding the mechanism of action of these immunologic interventions will facilitate the clinical development of these concepts and will also lead to the next generation of vaccines and eradication strategies. Focus 1: Understanding Mechanisms of Prophylactic SIV Vaccine Efficacy. We have developed two prophylactic vaccines with distinct and potentially complementary modes of protection against highly pathogenic mucosal SIV challenges. In Focus 1, we will explore the hypothesis that Ad26/Env and CMV vector vaccines protect by distinct and potentially complementary mechanisms. The major objectives are to determine the component or components of the humoral and/or cellular immune responses responsible for the efficacy of the Ad26/Env and CMV vector vaccines, the mechanisms by which these components prevent or control/clear infection, and their potential for combinatorial enhancement of efficacy.
Specific Aim 1 : To determine the nature and functional characteristics of antibodies responsible for protection against acquisition of infection in monkeys vaccinated with the Ad26/Env regimen.
Specific Aim 2 : To determine the cell type(s) (CD8+ T cells, CD4+ T cells, NK cells) responsible for CMV vector-mediated early control and eventual clearance of SIV infection, and the immunobiologic basis of protection vs. non-protection.
Specific Aim 3 : To determine whether combination of an acquisition-preventing Ab-targeted vaccine and an infection-controlling/clearing cellular immunity-targeted vaccine will add or synergize in protection. Focus 2: Development of Immunologic Strategies for SIV Remission/Eradication. Functional HIV cure will likely require both viral reservoir reduction and potent, long-term anti-viral immunity such that the viral reactivation that occurs after cART cessation can be eliminated or stringently controlled over a lifetime. In Focus 2, we will explore the hypothesis that therapeutic vaccines and engineered T cells, together with sanctuary disruption and potentially latency reversal, can contribute to virus eradication strategies.
Specific Aim 1 : To develop vaccine vector-based strategies to elicit T cell responses able to destroy reactivating virus during cART therapy and/or control viral relapse after cART cessation.
Specific Aim 2 : To develop engineered autologous T cell-based strategies to destroy reactivating virus during cART therapy and facilitate control of viral relapse after cART cessation.
Specific Aim 3 : To determine whether 2nd generation therapeutic vaccines combined with optimized latency reversal/sanctuary therapy can enhance SIV reservoir depletion and/or control post-cART viral relapse.

Public Health Relevance

Development of a safe and effective HIV-1 vaccine and HIV-1 cure are global health priorities. However, we currently lack the knowledge of how immune responses might be able to protect or to target viral reservoirs. In this program, we propose to define the mechanism of protection of leading HIV-1 vaccine candidates and immunologic strategies aimed at virus eradication in nonhuman primates.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Dang, Que
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Okoye, Afam A; Hansen, Scott G; Vaidya, Mukta et al. (2018) Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nat Med 24:1430-1440
Barouch, Dan H; Tomaka, Frank L; Wegmann, Frank et al. (2018) Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 392:232-243
Martinot, Amanda J; Abbink, Peter; Afacan, Onur et al. (2018) Fetal Neuropathology in Zika Virus-Infected Pregnant Female Rhesus Monkeys. Cell 173:1111-1122.e10
Badamchi-Zadeh, Alexander; Moynihan, Kelly D; Larocca, Rafael A et al. (2018) Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy. J Immunol 201:2744-2752
Alter, Galit; Barouch, Dan (2018) Immune Correlate-Guided HIV Vaccine Design. Cell Host Microbe 24:25-33
Badamchi-Zadeh, Alexander; Tartaglia, Lawrence J; Abbink, Peter et al. (2018) Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized Mice. J Virol 92:
Ram, Daniel R; Manickam, Cordelia; Hueber, Brady et al. (2018) Tracking KLRC2 (NKG2C)+ memory-like NK cells in SIV+ and rhCMV+ rhesus macaques. PLoS Pathog 14:e1007104
Bricault, Christine A; Kovacs, James M; Badamchi-Zadeh, Alexander et al. (2018) Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. J Virol :
Whitney, James B; Lim, So-Yon; Osuna, Christa E et al. (2018) Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy. Nat Commun 9:5429
Borducchi, Erica N; Liu, Jinyan; Nkolola, Joseph P et al. (2018) Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563:360-364

Showing the most recent 10 out of 25 publications